

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 November 2023 (16.11.2023)



(10) International Publication Number
WO 2023/220737 A2

(51) International Patent Classification:
C07H 21/02 (2006.01) A61K 31/712 (2006.01)

(21) International Application Number:
PCT/US2023/066961

(22) International Filing Date:
12 May 2023 (12.05.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/342,018 13 May 2022 (13.05.2022) US

(71) Applicant: ADARX PHARMACEUTICALS, INC.
[US/US]; 5871 Oberlin Drive, Suite 200, San Diego, CA
92121 (US).

(72) Inventors: LI, Zhen; c/o ADARx Pharmaceuticals, Inc.,
5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).
CHIRUTA, Chandramouli; c/o ADARx Pharmaceuticals,
Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121
(US). CHENG, Bo; c/o ADARx Pharmaceuticals, Inc.,
5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).
NUMA, Mehdi Michel, Djamel; c/o ADARx Pharmaceu-
ticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA
92121 (US). AZIMIOARA, Mihai; c/o ADARx Pharma-
ceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego,
CA 92121 (US). OLSSON, Chase, Robert; c/o ADARx
Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San
Diego, CA 92121 (US). ZHU, Rui; c/o ADARx Pharma-
ceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego,
CA 92121 (US).

(74) Agent: HSI, Jeffrey, D. et al.; Wolf, Greenfield & Sacks,
P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

WO 2023/220737 A2

(54) Title: OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF

(57) Abstract: Provided herein are oligonucleotide-containing compounds, methods of delivering the compounds, and methods of treating diseases, disorders, and symptoms (e.g., central nervous system diseases, disorders, and symptoms) in a subject using the compounds.